These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22444677)

  • 1. Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
    Odan M; Ishizuka N; Hiramatsu Y; Inagaki M; Hashizume H; Fujii Y; Mitsumori S; Morioka Y; Soga M; Deguchi M; Yasui K; Arimura A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2803-6. PubMed ID: 22444677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.
    Odan M; Ishizuka N; Hiramatsu Y; Inagaki M; Hashizume H; Fujii Y; Mitsumori S; Morioka Y; Soga M; Deguchi M; Yasui K; Arimura A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2898-901. PubMed ID: 22421019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.
    Odan M; Ishizuka N; Hiramatsu Y; Inagaki M; Hashizume H; Fujii Y; Mitsumori S; Morioka Y; Soga M; Deguchi M; Yasui K; Arimura A
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2894-7. PubMed ID: 22437111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones.
    Kusakabe K; Iso Y; Tada Y; Sakagami M; Morioka Y; Chomei N; Shinonome S; Kawamoto K; Takenaka H; Yasui K; Hamana H; Hanasaki K
    Bioorg Med Chem; 2013 Jun; 21(11):3154-63. PubMed ID: 23623258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.
    Kusakabe K; Tada Y; Iso Y; Sakagami M; Morioka Y; Chomei N; Shinonome S; Kawamoto K; Takenaka H; Yasui K; Hamana H; Hanasaki K
    Bioorg Med Chem; 2013 Apr; 21(7):2045-55. PubMed ID: 23395112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
    Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
    J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.
    Wrobleski ST; Chen P; Hynes J; Lin S; Norris DJ; Pandit CR; Spergel S; Wu H; Tokarski JS; Chen X; Gillooly KM; Kiener PA; McIntyre KW; Patil-Koota V; Shuster DJ; Turk LA; Yang G; Leftheris K
    J Med Chem; 2003 May; 46(11):2110-6. PubMed ID: 12747783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
    Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
    J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission.
    Haruna T; Soga M; Morioka Y; Hikita I; Imura K; Furue Y; Yamamoto M; Imura C; Ikeda M; Yamauchi A; Deguchi M; Shichijo M; Arimura A; Yasui K
    Pharmacology; 2015; 95(1-2):95-103. PubMed ID: 25721168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
    Reux B; Nevalainen T; Raitio KH; Koskinen AM
    Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
    Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
    Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
    J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
    van der Stelt M; Cals J; Broeders-Josten S; Cottney J; van der Doelen AA; Hermkens M; de Kimpe V; King A; Klomp J; Oosterom J; Pols-de Rooij I; de Roos J; van Tilborg M; Boyce S; Baker J
    J Med Chem; 2011 Oct; 54(20):7350-62. PubMed ID: 21923175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain.
    Bennett CE; Burnett DA; Greenlee WJ; Knutson CE; Korakas P; Li C; Tulshian D; Wu WL; Bertorelli R; Fredduzzi S; Grilli M; Lozza G; Reggiani A; Veltri A
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1575-8. PubMed ID: 22266036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
    Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
    J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
    Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
    J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
    J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
    Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.